

Dkt. 55293-JJPW/EN

GAU 1614
#5
S.B.
1-10-01
RECEIVED
DEC 29 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Carlos Cordon-Cardo, et al.
Serial No.: 09/329,917 Examiner: Not Yet Known
Filed : June 10, 1999 Group Art Unit: 1614
For : MARKERS FOR PROSTATE CANCER

1185 Avenue of the Americas
New York, New York 10036
December 19, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith a Supplemental Information Disclosure Statement under 37 C.F.R. §1.56.

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following disclosures:

1. U.S. Patent No. 5,688,665 (Massague et al.) issued November 18, 1997.
2. Cote, R.J., et al., (1998) "Association of p27^{Kip1} Levels With Recurrence and Survival in Patients With Stage C Prostate Carcinoma", J. Natl. Cancer Inst. 90(12): 916-920.

Carlos Cordon-Cardo, et al.
Serial No.: 09/329,917
Filed: June 10, 1999
Page 2

RECEIVED
DEC 29 2000
TECH CENTER 1600/2900

3. Lloyd, et al., (1999) "A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers", American Journal Pathology, 154(2):313-323.
(Exhibit 1)

The subject application is a continuation-in-part of PCT International Application No. PCT/US98/25483, filed December 1, 1998, claiming benefit of U.S. Provisional Application No. 60/067,190, filed December 1, 1997. Each of the above-listed references is listed on the accompanying PTO Form 1449 as **Exhibit A**.

Above-listed publications 1-3 were cited in the International Search Report in connection with related copending PCT International Application No. PCT/US00/16007, filed on June 2, 2000, which claims priority of the subject application. A copy of the International Search Report is attached hereto as **Exhibit B**. A copy of publication 3 is attached hereto as **Exhibit 1**; copies of above-listed publications 1-2 were previously submitted to the U.S. Patent and Trademark Office in an I.D.S. in connection with the subject application.

Under 37 C.F.R. §1.97(b)(3) an information disclosure statement (I.D.S.) shall be considered by the U.S. Patent Office if filed before the mailing of a first Office Action on the merits. Accordingly, this Supplemental Information Disclosure Statement is

Carlos Cordon-Cardo, et al.
Serial No.: 09/329,917
Filed: June 10, 1999
Page 3

filed before the mailing of a first Office Action on the merits.

Applicants request that the Examiner review the above-listed publications and make them of record in the subject application.

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.


No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully yours,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.


John P. White
Reg. No. 28,678

12/19/00
Date